Abstract
The present disclosure relates to immunoglobulins that bind FcγRIIb+ B cells and coengage CD19 on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins for the treatment of an IgG4-related disease.
Full Text
What is claimed is:
The present disclosure relates to immunoglobulins that bind FcγRIIb+ B cells and coengage CD19 on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins for the treatment of an IgG4-related disease.
Timeline
Filed
05/05/2026Published
08/27/2026Granted
Not AvailableIPC Codes(4)
C07K 16/28:against receptors, cell surface antigens or cell surface determinants
A61K 39/00:Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N 33/53)
A61K 39/395:Antibodies (agglutinins A61K 38/36); Immunoglobulins; Immune serum, e.g. antilymphocytic serum